Epalrestat-d5
Based on 1 Customer Validation
Epalrestat-d5 is deuterium labeled Epalrestat. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2755644-33-6
- Formule: C15H8D5NO3S2
- Masse moléculaire:324.43
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 2755644-33-6
-
Unlabeled Cas 82159-09-9
-
Masse moléculaire 324.43
-
Formule C15H8D5NO3S2
-
SMILES
O=C(N1CC(O)=O)/C(SC1=S)=C/C(C)=C/C2=C(C([2H])=C(C([2H])=C2[2H])[2H])[2H]
-
Synonyms
ONO2235-d5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvant et solubilité
DMSO : 20 mg/mL (61.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
Références
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55. [Content Brief]
[3]. He J, et al. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. Acta Pharmacol Sin. 2019 Jan;40(1):86-97. [Content Brief]
[4]. Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64. [Content Brief]
[5]. Sato K, et al. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. Redox Biol. 2013 Nov 19;2:15-21. [Content Brief]
[6]. Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10(3): p. 168-72. [Content Brief]
[7]. Li QR, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res. 2016 Feb;11(2):345-51. [Content Brief]
[8]. Zhang T, et al. The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia. Mol Neurobiol. 2023 Jul;60(7):3741-3757. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0823 mL | 15.4116 mL | 30.8233 mL | 77.0582 mL |
| 5 mM | 0.6165 mL | 3.0823 mL | 6.1647 mL | 15.4116 mL | |
| 10 mM | 0.3082 mL | 1.5412 mL | 3.0823 mL | 7.7058 mL | |
| 15 mM | 0.2055 mL | 1.0274 mL | 2.0549 mL | 5.1372 mL | |
| 20 mM | 0.1541 mL | 0.7706 mL | 1.5412 mL | 3.8529 mL | |
| 25 mM | 0.1233 mL | 0.6165 mL | 1.2329 mL | 3.0823 mL | |
| 30 mM | 0.1027 mL | 0.5137 mL | 1.0274 mL | 2.5686 mL | |
| 40 mM | 0.0771 mL | 0.3853 mL | 0.7706 mL | 1.9265 mL | |
| 50 mM | 0.0616 mL | 0.3082 mL | 0.6165 mL | 1.5412 mL | |
| 60 mM | 0.0514 mL | 0.2569 mL | 0.5137 mL | 1.2843 mL |
Epalrestat-d5 Related Classifications
HY-W653944 Related Classifications
Powered by Bioz